Public Employees Retirement System of Ohio Has $2.68 Million Stock Holdings in BeiGene, Ltd. (NASDAQ:BGNE)

Public Employees Retirement System of Ohio decreased its position in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 73.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,917 shares of the company's stock after selling 32,483 shares during the period. Public Employees Retirement System of Ohio's holdings in BeiGene were worth $2,675,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of BGNE. Blue Trust Inc. boosted its position in BeiGene by 156.3% during the third quarter. Blue Trust Inc. now owns 123 shares of the company's stock valued at $28,000 after purchasing an additional 75 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of BeiGene in the third quarter worth about $36,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BeiGene in the third quarter worth about $67,000. SG Americas Securities LLC acquired a new stake in shares of BeiGene in the third quarter worth about $105,000. Finally, PFG Investments LLC acquired a new stake in shares of BeiGene in the third quarter worth about $210,000. Institutional investors and hedge funds own 48.55% of the company's stock.

Insider Activity at BeiGene

In other news, insider Lai Wang sold 5,000 shares of the company's stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $220.35, for a total value of $1,101,750.00. Following the sale, the insider now directly owns 920,920 shares in the company, valued at approximately $202,924,722. This represents a 0.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Xiaobin Wu sold 4,500 shares of the company's stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $200.14, for a total value of $900,630.00. The disclosure for this sale can be found here. Insiders have sold 1,136,122 shares of company stock worth $213,421,417 over the last three months. Company insiders own 7.43% of the company's stock.

Analyst Upgrades and Downgrades

BGNE has been the subject of a number of analyst reports. JMP Securities initiated coverage on BeiGene in a research report on Wednesday, September 18th. They issued a "market outperform" rating and a $288.00 price target for the company. Morgan Stanley reaffirmed an "overweight" rating and issued a $300.00 price target on shares of BeiGene in a research report on Tuesday, December 3rd. TD Cowen boosted their price target on BeiGene from $254.00 to $260.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. StockNews.com cut BeiGene from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Finally, JPMorgan Chase & Co. boosted their price objective on BeiGene from $200.00 to $235.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 22nd. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $253.69.

BeiGene Stock Performance

BGNE traded up $2.73 on Tuesday, hitting $179.06. 300,270 shares of the stock traded hands, compared to its average volume of 283,150. BeiGene, Ltd. has a 52 week low of $126.97 and a 52 week high of $248.16. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $17.45 billion, a PE ratio of -21.64 and a beta of 0.57. The business has a fifty day moving average price of $205.89 and a two-hundred day moving average price of $187.30.

BeiGene (NASDAQ:BGNE - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. During the same quarter in the prior year, the firm earned $2.01 earnings per share. The company's revenue was up 28.2% on a year-over-year basis. On average, research analysts predict that BeiGene, Ltd. will post -5.64 EPS for the current fiscal year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.